GIO World Health, a life sciences company, agreed to go public via a SPAC merger with Apeiron Capital Investment Corp, a special purpose acquisition company, in a $250m deal. “We are delighted to partner with Apeiron Capital in this business combination, a significant milestone toward creating value for our shareholders. This business combination and entry into the public markets will allow us access to a much larger pool of capital and increase our global profile for several clinical trials. We believe that this Transaction will put us in a position to quickly grow in what we see as a $100bn+ industry in the U.S. and global market that is projected to grow at a 10+% CAGR,” Deven Patel, GIO World Health CEO.